Adherium Ltd. · ASX:ADR
Adherium — Shareholder Meeting (November 2019)
15 slides from Adherium's shareholder meeting presentation, November 2019
Slide 1: Adherium: CEO Presentation to AGM
Adherium: CEO Presentation to AGM November 2019
Slide 2: Disclaimer and Forward looking Statement
CONFIDENTIAL adherium % Disclaimer and Forward looking Statement The following material is of a general nature and has only been prepared as a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adherium Limited ACN 605 352 510 (Adherium or
Slide 3: Adherium Overview
CONFIDENTIAL adherium Adherium Overview Digital health company, founded in 20014 and listed on ASX in 2015 A leader in providing connected health solutions to the respiratory health community with a primary focus on enhancing adherence among asthma patients supported by: © Our Hailie® sensor technol
Slide 4: With years of experience in adherence technology, Adherium is well positioned
~) S| S| Z| i) S| a Z| fe) [S) adherium % With 17 years of experience in adherence technology, Adherium is well positioned to address the digital health adherence opportunity with partners Why Adherence Technology? ee US$56b US economic burden of asthma Why now? Changing market conditions triggering
Slide 5: In the last four years, we have made significant progress
CONFIDENTIAL adherium “ In the last four years, we have made significant progress to enhance and distribute our technology, while preparing for growth oO Commercial @ Product “470,000 sensors sold globally Sensor set with broad US market coverage for asthma (80%) @ Further development of our relatio
Slide 6: Sensor R&D delivered six new devices
CONFIDENTIAL Hailie® for Symbicort® pMDI Hailie® for Ventolin® Sensor R&D delivered six new devices Hailie® for Bevespi® Hailie® for Symbicort® Turbuhaler® adherium % Hailie® for Diskus® ae Hailie® for Handihaler®
Slide 7: Manufacturing & Regulatory: 159k sensors shipped in last four years
adherium� Manufacturing & Regulatory: 159k sensors shipped in last four years upgraded to 2016 standard and EU Notified Body auditor. FDA audit in 2019 with no 159k devices shipped. Boehringer lngelheim's Supported supplier in HandiHaler, AZ's gaining ISO 13485 Bevespi and Symbicort, accreditation G
Slide 8: Medication non-adherence among asthma and COPD patients has significant impact
CONFIDENTIAL adherium Medication non-adherence among asthma and COPD patient has a particularly significant clinical and cost impact on the healthcare system Ee ae 10% higher risk of hospital admissions O for children with <50% adherence Asthma & COPD patients annual preventable US healthcare only t
Slide 9: Adherium's Hailie solution has improved medication adherence
CONEFIDENTIAL adherium % Adherium’s Hailie® solution, with over 85 peer reviewed journals, has improved medication adherence among asthma and COPD patients es Patients Clinicians & Providers tidal dl t'tti Hailie® Sensor —__Hailie® Mobile App Hailie® Clinician Web Portal Patients know when they have
Slide 10: Clinical research involving the Hailie solution demonstrates significant health outcomes
Clinical research involving the Hailie® solution demonstrates significant health outcomes 5 , Monitoring the use of asthma medication with Hailie® reduces the frequency of negative outcomes . a | ¥Y gs B) Se 7 AM ces ig "= 6 dose 18.9 Aone REN ce (is = € Hospital Acute Missed Reliever Steroid Missed
Slide 11: Hailie solution helps drive significant healthcare cost savings
CONFIDENTIAL adherium By enhancing adherence and patient outcomes, the Hailie® solution also helps drive significant healthcare cost savings Asthma & COPD patients using Hailie® sensors take estimated “80% O of their daily prescribed doses instead of 50%, leading to... “2 Less = $17b & 59% attacks a
Slide 12: Based on learnings, we have a new focus to address the opportunity
adherium % Based on learnings from our experience and evolving market conditions, we have now a new focus to address the opportunity Changing Market Conditions Our New Focus Healthcare needs to do more with less in a context of a changing healthcare environment Payer- and provider-led strategies, as
Slide 13: Proven Leadership Team
CONFIDENTIAL Proven Leadership Team adherium % ® Adding significant commercialisation strategy experience with proven track record in US, APAC and RoW ——-9-——— Thomas Lynch Chairman @ Moved multiple offshore companies to the US @ Chairman of multiple multi- billion healthcare companies @ Deep connec
Slide 14: Conclusion
CONFIDENTIAL Fs) adherium % Conclusion Key Drivers... Ever growing burden of respiratory and broader chronic diseases 25m asthma patients in the US Urge to contain costs while enhancing clinical outcomes $56b US economic burden of asthma Evolving patients base - living longer, with chronic diseases,
Slide 15: War ay
War ay